Description

Sotorasib is a highly selective and potent small molecule inhibitor targeting the KRAS G12C mutant protein, a key oncogenic driver in several cancers. This targeted therapy represents a significant advancement in precision oncology, offering a direct approach to treating tumors harboring this specific mutation. It is primarily utilized by pharmaceutical manufacturers, research institutions, and clinical laboratories engaged in the development and production of innovative cancer therapeutics. Sotorasib CAS NO 2296729-00-3 is a critical active pharmaceutical ingredient (API) for formulating finished dosage forms.

Application

• Pharmaceutical API: Primary use as the active ingredient in the commercial manufacture of targeted cancer therapy drugs.
• Oncology Research: A vital reference standard and tool compound for studying KRAS G12C signaling pathways, drug resistance mechanisms, and combination therapies.
• Preclinical & Clinical Development: Serves as the key material for formulation studies, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and clinical trial material (CTM) production.
• Biochemical Assays: Used in high-throughput screening (HTS) and in vitro assays to evaluate the potency and selectivity of KRAS G12C inhibition.
• Drug Discovery: A benchmark compound for the design and synthesis of next-generation KRAS inhibitors and related oncogenic target modulators.

Basic Information

Product Name	Sotorasib
CAS No.	2296729-00-3
Molecular Formula	C30H30F2N6O3
Molecular Weight	560.60 g/mol
Synonyms	AMG 510; Lumakras (Trade Name); Lumykras (Trade Name); (R)-1-(2,2-Difluoro-2H-1,3-benzodioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-2-oxo-1,2-dihydropyridin-3-yl)cyclopropanecarboxamide; KRAS G12C Inhibitor AMG-510
EINECS	Contact for details

Quality Control

Our Sotorasib is manufactured under strict quality management systems to ensure it meets the stringent requirements for pharmaceutical active ingredients. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We adhere to current Good Manufacturing Practices (cGMP) and can supply material suitable for use in clinical and commercial drug product manufacturing. Certificates of Analysis (COA) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15-25°C (59-77°F). The product is light-sensitive and should be handled under appropriate conditions to maintain stability and potency. Keep the container in a dry, well-ventilated place.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms
Identification (IR)	Conforms to reference spectrum
Assay (HPLC)	≥98.5%
Related Substances (HPLC)	Total impurities ≤1.5% Any single unknown impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤20 ppm
Water Content (KF)	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.